Cicletanine-induced hyponatremia and hypokalemia in kidney transplant patients.
BACKGROUND
Cicletanine is an antihypertensive agent with vasorelaxant and diuretic properties. It has been widely used in European countries; however, cicletanine-associated electrolyte disturbances have yet to be defined. We investigated cicletanine-induced hyponatremia and hypokalemia in kidney transplant patients.


METHODS
Data from a total of 68 kidney transplant recipients who were treated for hypertension with cicletanine were retrospectively analyzed. Cicletanine-induced hyponatremia and hypokalemia were defined as serum sodium < 135 mmol/L and potassium < 3.5 mmol/L, respectively, after the use of cicletanine.


RESULTS
The average patient age was 50 (±11) years, and 44 (65%) were male. The daily dose of cicletanine was 171 ± 46 mg, and the duration of drug use was 215 ± 514 days. Hyponatremia occurred in 11 patients (16.2%), and hypokalemia occurred in 8 patients (11.8%). Three patients (4.4%) had hyponatremia and hypokalemia simultaneously. The duration of cicletanine administration was significantly longer in patients with hyponatremia than in those without hyponatremia (943 ± 958 vs. 74 ± 166 days, P < 0.05). The occurrence of hypokalemia was not affected by either daily dose or duration of drug use. Among 11 patients with hyponatremia, 10 were corrected within 2 weeks after withdrawal of the drug and 1 was spontaneously corrected. Among 8 cases of hypokalemia, 7 were corrected after withdrawal of the drug and 1 was spontaneously corrected.


CONCLUSIONS
We demonstrate that cicletanine may induce hyponatremia or hypokalemia in kidney transplant patients. Hyponatremia is more frequently associated with cicletanine than hypokalemia, and extended use of cicletanine may increase the risk of hyponatremia.
Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.
Eun Young
EY
Choi
Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.
Youngouk
Y
Ro
Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.
Jong-Wook
JW
Choi
Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.
Chong Myung
CM
Kang
Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.
Gheun-Ho
GH
Kim
Cicletanine; Hypokalemia; Hyponatremia; Kidney transplantation
Arch Mal Coeur Vaiss. 1989 Nov;82 Spec No 4:135-8
2514653
Am J Kidney Dis. 2014 Feb;63(2):294-303
24239050
J Hypertens. 2012 Apr;30(4):819-27
22278145
Arch Mal Coeur Vaiss. 1999 Aug;92(8):1001-4
10486654
J Am Soc Nephrol. 2015 Jun;26(6):1248-60
25653099
J Pharmacol Exp Ther. 1995 Jun;273(3):1190-6
7791090
Br J Clin Pharmacol. 2006 Jan;61(1):87-95
16390355
Arch Mal Coeur Vaiss. 1989 Nov;82 Spec No 4:91-7
2514675
Gen Pharmacol. 1999 Jul;33(1):7-16
10428010
Cardiovasc Ther. 2012 Oct;30(5):e219-26
21884020
Am J Hypertens. 1997 Jul;10(7 Pt 1):750-5
9234829
Klin Wochenschr. 1988 Aug 1;66(15):662-9
3050265
BMJ. 2006 Mar 25;332(7543):702-5
16565125
Eur J Clin Pharmacol. 1990;39(3):227-32
2257857
J Am Soc Nephrol. 1997 Jul;8(7):1179-88
9219169
Am J Hypertens. 1994 Jun;7(6):550-4
7917154
Drugs Exp Clin Res. 1988;14(2-3):205-14
3046884
Ren Fail. 2014 Apr;36(3):345-50
24345270
Am J Kidney Dis. 2013 Jul;62(1):67-72
23602191
Pharmacogenomics. 2014 Jun;15(9):1243-51
25141899